Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Patent
1996-10-22
1999-08-10
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
424451, 424464, 514553, 514561, A61K 914, A61K 948, A61K 920
Patent
active
059356014
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to compositions suitable for drug delivery, and in particular to compositions in which modified amino acids or peptides are used as carriers for biologically active agents including, but not limited, to bioactive peptides and the like. The modified amino acids or peptides can form non-covalent mixtures or microspheres with biologically-active agents and are suitable for oral administration to animals. Methods for the preparation and for the administration of such compositions are also disclosed.
BACKGROUND OF THE INVENTION
Conventional means for delivering biologically-active agents, including, but not limited to, pharmaceutical and therapeutic agents to animals often are severely limited by chemical and physical barriers imposed by the body. Oral delivery of many biologically-active agents would be the route of choice if not for the presence of chemical and physico-chemical barriers such as extreme and varying pH in the gastro-intestinal (GI) tract, exposure to powerful digestive enzymes, and impermeability of gastro-intestinal membranes to the active ingredient. Among the numerous pharmacological agents which are not suitable for oral administration are biologically-active peptides such as calcitonin and insulin. Examples of other compounds which are affected by the physico-chemical barriers are polysaccharides and mucopolysaccharides, including, but not limited to, heparin, heparinoids, antibiotics and other organic substrates. These agents are rapidly destroyed in the gastro-intestinal tract by acid hydrolysis, enzymes, or the like.
Prior methods for orally administering vulnerable pharmacological agents have relied on co-administration of adjuvants (e.g., resorcinols and non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether) to increase artificially the permeability of the intestinal walls; and on co-administration of enzymatic inhibitors (e.g., pancreatic trypsin inhibitor, diisopropylfluorophosphate (DFF) and trasylol) to avoid enzymatic degradation. Liposomes have also been described as drug delivery systems for insulin and heparin. See, for instance, U.S. Pat. No. 4,239,754; Patel et al. (1976) FEBS Letters Vol. 62, page 60; and Hashimoto et al. (1979) Endocrinol. Japan, Vol. 26, page 337. The broader use of the aforementioned methods, however, as drug delivery systems are precluded for reasons which include: (1) the use of toxic amounts of adjuvants or inhibitors; (2) the lack of suitable low MW cargoes; (3) the poor stability and inadequate shelf life of the systems; (4) difficulty in manufacturing; and (5) the failure of the systems to protect the active ingredient; and (6) the failure of the systems to promote absorption of the active agent.
More recently, microspheres of artificial polymers, or proteinoids, of mixed amino acids have been described for delivery of pharmaceuticals. For example, U.S. Pat. No. 4,925,673 describes such microspheres as well as methods for their preparation and use. The proteinoid microspheres of the '673 patent are useful for encapsulating a number of active agents.
There is a need in the art for a simple and inexpensive delivery system which is easily prepared and which can deliver a broad range of biologically-active agents.
SUMMARY OF THE INVENTION
Compositions for delivering biologically-active agents incorporating modified amino acids as carriers are provided. The compositions comprise; being substituted with C.sub.1 -C.sub.7 alkyl, C.sub.2 -C.sub.7 alkenyl, C.sub.1 -C.sub.7 alkoxy, hydroxy, phenyl, phenoxy, or --CO.sub.2 R, wherein R is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.2 -C.sub.4 alkenyl; or acylating agent.
In an alternative embodiment, these compositions are used in oral dosage unit forms. The compositions or oral dosage unit forms can be orally administered to animals.
DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graphic illustration of the results of oral gavage testing in rats using calcitonin with cyclohexanoyl-(L)-leucine, cycloheptanoyl-(L)-leucine and 2-methylcyclohexan
REFERENCES:
patent: Re24899 (1960-11-01), Green
patent: 3052655 (1962-09-01), Fox et al.
patent: 3076790 (1963-02-01), Fox et al.
patent: 3491093 (1970-01-01), Pachter et al.
patent: 3567650 (1971-03-01), Bakan
patent: 3574832 (1971-04-01), Engel et al.
patent: 3687926 (1972-08-01), Arima et al.
patent: 3794561 (1974-02-01), Matsukawa et al.
patent: 3795739 (1974-03-01), Birkmayer et al.
patent: 3816404 (1974-06-01), Kablaoui et al.
patent: 3822348 (1974-07-01), Higashi et al.
patent: 3933873 (1976-01-01), Love et al.
patent: 3939253 (1976-02-01), Bodor et al.
patent: 3956172 (1976-05-01), Saeki et al.
patent: 3962416 (1976-06-01), Katzen
patent: 3976773 (1976-08-01), Curran
patent: 4035507 (1977-07-01), Bodor et al.
patent: 4061466 (1977-12-01), Sjoholm et al.
patent: 4117801 (1978-10-01), Dannelly et al.
patent: 4199561 (1980-04-01), Roth et al.
patent: 4239635 (1980-12-01), Rieder
patent: 4272506 (1981-06-01), Schwarzberg
patent: 4289759 (1981-09-01), Heavner et al.
patent: 4388304 (1983-06-01), Nyeki et al.
patent: 4393192 (1983-07-01), Curatolo et al.
patent: 4402856 (1983-09-01), Schnoring et al.
patent: 4405598 (1983-09-01), Brown
patent: 4442090 (1984-04-01), Kakeya et al.
patent: 4460563 (1984-07-01), Calanchi
patent: 4462839 (1984-07-01), McGinley et al.
patent: 4462991 (1984-07-01), Higuchi et al.
patent: 4473620 (1984-09-01), Wu et al.
patent: 4518433 (1985-05-01), McGinley et al.
patent: 4590265 (1986-05-01), Bogan et al.
patent: 4613500 (1986-09-01), Suzuki et al.
patent: 4647455 (1987-03-01), De Bold
patent: 4673566 (1987-06-01), Goosen et al.
patent: 4690786 (1987-09-01), Ninomiya et al.
patent: 4692284 (1987-09-01), Braden
patent: 4703042 (1987-10-01), Bodor
patent: 4708952 (1987-11-01), Salatinjants
patent: 4757024 (1988-07-01), Roper
patent: 4757066 (1988-07-01), Shiokari
patent: 4766012 (1988-08-01), Valenti
patent: 4774320 (1988-09-01), Tagliabue et al.
patent: 4789734 (1988-12-01), Pierschbacher
patent: 4837381 (1989-06-01), Steber et al.
patent: 4844904 (1989-07-01), Hamaguchi et al.
patent: 4873087 (1989-10-01), Morishita
patent: 4886663 (1989-12-01), Houghten
patent: 4897444 (1990-01-01), Brynes et al.
patent: 4900730 (1990-02-01), Miyauchi
patent: 4908233 (1990-03-01), Takizawa et al.
patent: 4919939 (1990-04-01), Baker
patent: 4925673 (1990-05-01), Steiner
patent: 4996292 (1991-02-01), Fox et al.
patent: 5019400 (1991-05-01), Gombotz et al.
patent: 5023374 (1991-06-01), Simon
patent: 5039481 (1991-08-01), Pacifici et al.
patent: 5066487 (1991-11-01), Morrelle
patent: 5067961 (1991-11-01), Kelman et al.
patent: 5077278 (1991-12-01), Hafner et al.
patent: 5100918 (1992-03-01), Sunshine et al.
patent: 5122367 (1992-06-01), Ron et al.
patent: 5126147 (1992-06-01), Silvestri et al.
patent: 5137892 (1992-08-01), Chu et al.
patent: 5186947 (1993-02-01), Goettsche et al.
patent: 5216124 (1993-06-01), Hansen, Jr. et al.
patent: 5244653 (1993-09-01), Berke et al.
patent: 5271934 (1993-12-01), Goldberg et al.
patent: 5271961 (1993-12-01), Mathiowitz et al.
patent: 5328992 (1994-07-01), Peter et al.
patent: 5352461 (1994-10-01), Feldstein et al.
patent: 5389377 (1995-02-01), Chagnon et al.
patent: 5389379 (1995-02-01), Dirix et al.
patent: 5536813 (1996-07-01), Charpenel et al.
patent: 5578323 (1996-11-01), Milstein et al.
patent: 5601846 (1997-02-01), Milstein et al.
patent: 5705529 (1998-01-01), Matyus et al.
Kondo, Microcapsule Processing and Technology, pp. 154-165, 1979.
Pastores et al., Journal of Liquid Chromatography, 18:3049-3059, 1995.
Sinha et al., Journal of Biological Chemistry, 260:10714-10719, 1985.
Franssen et al., J. Med. Chem., 35:1246-1259, 1992.
Chemical Abstract, pp(23):191473h, Dec. 5, 1983.
Butera et al., J. Med. Chem., 34:3212-3228, 1990.
Cimini et al., Ann. Rept. in Med. Chem., 27:89-98, 1992.
Earley et al., Brain Research, 546:282-286, 1991.
Ellingboe et al., J. Med. Chem., 35:705-716, 1992.
Lumma et al., J. Med. Chem., 30:758-763, 1987.
Lynch et al., J. Pharm. and Exp. Therap., 269:541-554, 1994.
Matsuno et al., Br
Leone-Bay Andrea
Wang Nai Fang
Emisphere Technologies Inc.
Kishore Gollamudi S.
LandOfFree
Modified amino acids for drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified amino acids for drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified amino acids for drug delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1117720